Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio

The Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test is an in vitro blood test that combines the results of Lumipulse G pTau 217 and β-Amyloid 1-42 into a ratio of pTau 217 to β-Amyloid 1-42 concentration using the LUMIPULSE G1200. 

For in vitro diagnostic use
Lumipulse® G pTau 217 Plasma IRC

Product # 81550

3 x 14 Tests
Lumipulse® G β-Amyloid 1-42-N Plasma IRC

Product # 235447

3 x 14 Tests
Lumipulse® G pTau 217 Plasma CAL

Product # 81557

1 x 5 Concentrations
Lumipulse® G β-Amyloid 1-42-N Plasma CAL

Product # 235454

1 x 4 Concentrations
Lumipulse® pTau 217 Plasma Controls

Product # 81558

2 x 2 Concentrations
Lumipulse® β-Amyloid Plasma Controls

Product # 81559

2 x 2 Concentrations
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Details
  • Citations
  • Documentation
  • Insights
  • Related products

  • Details

    Please note: precaution

    The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio must be calculated using the results obtained from Lumipulse G pTau 217 Plasma and Lumipulse G β-Amyloid 1-42-N Plasma on the same patient sample and same LUMIPULSE G1200 analyzer. Use of another manufacturer’s assays may result in significantly different ratios. pTau 217 and β-amyloid 1-42 values determined on patient samples using other manufacturers’ assays cannot be interchangeably used to calculate the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio which could lead to wrong diagnostic conclusions.
    The Lumipulse G pTau 217 Plasma assay should only be used with the Lumipulse G β-Amyloid 1-42-N Plasma assay to calculate the ratio of pTau 217/β-amyloid 1-42. The Lumipulse G pTau 217 Plasma and the Lumipulse G β-Amyloid 1-42-N Plasma assays are not intended to be used individually.

     

     

    For more information, click here

  • Citations

    The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

  • Insights

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.